Psyence Labs Ltd. disclosed a 30.05% stake in PSYENCE BIOMEDICAL LTD.’s common shares. The stake stems from a share‑for‑share exchange completed on Feb. 25, 2026, and was reported in a Schedule 13D filed on Jun. 03, 2026. The exchange valued Psyence Labs’ contribution at $5 million and gave it sole voting and dispositive power over 1,146,159 shares.
Investor Intent
Psyence Labs holds the shares for investment and will keep reviewing the position. It may “acquire additional Common Shares” or “dispose of any or all of the Securities,” and could use hedging, while it currently has no specific plans for corporate changes.
Investor’s Background
Psyence Labs Ltd. is a British Virgin Islands company that cultivates, manufactures, and supplies nature-derived psychedelic active pharmaceutical ingredients, including pharmaceutical-grade ibogaine and psilocybin. The company focuses on regulated research and medical markets for psychedelic compounds. It invests strategically in related ventures to support development and commercialization of these therapies.
Original SEC Filing: PSYENCE BIOMEDICAL LTD. [ PBM ] – SCHEDULE 13D – Jun. 03, 2026
